Navigation Links
Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
Date:3/11/2010

THOUSAND OAKS, Calif., March 11 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the methods of expressing, secreting, and purifying the NELL-1 sequence of the UCB-1 recombinant protein wherein the mammalian cell line comprises a Chinese hamster ovary (CHO) cell. This patent continues the creation of a patent portfolio for musculoskeletal applications of manufacturing and use in bone regeneration and repair as well as cartilage regeneration and repair.  

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA.  The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort. This platform technology is combined with DBX® demineralized bone matrix, to promote bone growth in spinal fusion. DBX® is a product of the Musculoskeletal Transplant Foundation, a Bone Biologics partner.  

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.    

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. said, "This patent issuance is a significant milestone in our efforts to realize the full potential of the UCB-1 protein as a platform technology. We very much appreciate the continued support of MTF on this project."

"We are pleased to continue our partnership with Bone Biologics," noted Bruce Stroever, CEO of MTF. "This latest patent issuance is a clear sign that the company is continuing to make very good progress toward FDA approval and commercialization of an important product."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space.  The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years.  The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.

For information: Bruce A. Hazuka/Bone Biologics/818-324-2742

SOURCE Bone Biologics, Inc.

Back to top
'/>"/>
SOURCE Bone Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clive Dix Appointed as Chairman of Crescendo Biologics
2. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
3. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
4. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
5. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
6. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
7. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
8. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
9. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):